These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11939682)

  • 1. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study.
    Florea NR; Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
    Am J Health Syst Pharm; 2003 Nov; 60(22):2321-7. PubMed ID: 14652981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
    DeRyke CA; Kuti JL; Mansfield D; Dana A; Nicolau DP
    Am J Health Syst Pharm; 2006 Apr; 63(8):750-5. PubMed ID: 16595817
    [No Abstract]   [Full Text] [Related]  

  • 4. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementation of an extended-infusion piperacillin-tazobactam program at an urban teaching hospital.
    Xamplas RC; Itokazu GS; Glowacki RC; Grasso AE; Caquelin C; Schwartz DN
    Am J Health Syst Pharm; 2010 Apr; 67(8):622-8. PubMed ID: 20360589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
    McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
    Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing.
    Burgess DS; Waldrep T
    Clin Ther; 2002 Jul; 24(7):1090-104. PubMed ID: 12182254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and Economic Impact of Empirical Extended-Infusion Piperacillin-Tazobactam in a Community Medical Center.
    Brunetti L; Poustchi S; Cunningham D; Toscani M; Nguyen J; Lim J; Ding Y; Nahass RG
    Ann Pharmacother; 2015 Jul; 49(7):754-60. PubMed ID: 25855703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
    Schmees PM; Bergman SJ; Strader BD; Metzke ME; Pointer S; Valenti KM
    Am J Health Syst Pharm; 2016 Jun; 73(11 Suppl 3):S100-5. PubMed ID: 27208142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.
    Lau WK; Mercer D; Itani KM; Nicolau DP; Kuti JL; Mansfield D; Dana A
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3556-61. PubMed ID: 16940077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical and economic benefits of administering piperacillin-tazobactam by continuous infusion.
    Kotapati S; Kuti JL; Geissler EC; Nightingale CH; Nicolau DP
    Intensive Crit Care Nurs; 2005 Apr; 21(2):87-93. PubMed ID: 15778072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion.
    Buck C; Bertram N; Ackermann T; Sauerbruch T; Derendorf H; Paar WD
    Int J Antimicrob Agents; 2005 Jan; 25(1):62-7. PubMed ID: 15620828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of Extended Versus Intermittent Infusion of Piperacillin/Tazobactam in Critically Ill Patients: A Prospective Clinical Trial.
    Fan SY; Shum HP; Cheng WY; Chan YH; Leung SM; Yan WW
    Pharmacotherapy; 2017 Jan; 37(1):109-119. PubMed ID: 27888542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?
    Attivi D; Gibaud S
    Ann Pharm Fr; 2014 May; 72(3):146-51. PubMed ID: 24780830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
    Lodise TP; Lomaestro B; Drusano GL
    Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.
    Dietrich ES; Schubert B; Ebner W; Daschner F
    Pharmacoeconomics; 2001 Jan; 19(1):79-94. PubMed ID: 11252548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
    Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
    Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.
    Bao H; Lv Y; Wang D; Xue J; Yan Z
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):459-466. PubMed ID: 27796647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: results of an open randomized trial at a university hospital.
    Oztoprak N; Piskin N; Aydemir H; Celebi G; Akduman D; Keskin AS; Gokmen A; Engin H; Ankarali H
    Jpn J Clin Oncol; 2010 Aug; 40(8):761-7. PubMed ID: 20427546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.